Immunostics Launches COVID-19 Point-of-Care Test to Detect Novel Coronavirus in less than 10 Minutes

Updated: Apr 6


EATONTOWN N.J. - Mar. 30, 2020 Immunostics Inc is announcing the release of our Afias-1/6, COVID-19 test. This test is intended for the point-of-care use to deliver results in less than ten minutes.


Immunostics AFIAS COVID-19 test is truly innovative using fingerstick blood samples to provide results in 10 minutes


Immunostics AFIAS platform is a small and portable instrument that can be deployed anywhere to enable rapid COVID-19 testing wherever needed


Immunostics point-of-care AFIAS platform does not require swabs and other related materials making testing simple and easy


AFIAS-6 can perform 36 COVID-19 tests per hour.

Immunostics AFIAS COVID-19 tests are available now and will have the capacity to deliver 20,000 tests per day. Immunostics expects to be able to ramp up our manufacturing abilities to deliver 40,000 tests per day by May 2020


AFIAS COVID-19 platform are able to deliver up to 36 results per hour ( e.g. 6 tests per hour for AFIAS-1; 36 tests per hour for AFIAS-6)


AFIAS comes with full connectivity (LAN, USB, RS232) and can store 5,000 patient results


According to Dr. Gianrico Farrugia, CEO Mayo Clinic, "the serology antibody test is very important to understand who has an antibody and therefore can be presumed to have had contact with the virus and has mounted a response to it."


Please contact adamchoe@immunostics.com for more info.


#COVID19

#SARSCOV2

#immunostics

#poct

#newjersey

#healthnews

1,842 views

Visitors

We offer special rates at

 Homewood Suites by Hilton

Eatontown New Jersey 

Click here to book you room

Analyzers

AFIAS-1

AFIAS-6

hemochroma PLUS

ALFIS-3

Fecal Occult Blood

hema-screen SPECIFIC

Company

Contact Us

Updates

News

Immunostics, Inc

38 Industrial Way Ste.1

Eatontown, NJ, 07724 USA

Phone:

732-918-0770

1-800-722-7505

Fax:

732-918-0618

Email:

sales@immunostics.com

Hours of Operation:

Mon - Fri  8am - 430pm EST

Copyright 2019 Immunostics Inc.